Aim: To comparing furazolidone and tetracycline in quadruple therapy for eradication of helicobacter pylori in dyspepsia patients.
Background: Helicobacter pylori eradication is the main step in dyspepsia and peptic ulcer management. In Iran different regimens have been proposed, however, most of our patients are resistant to metronidazole. In the current study we compared furazolidone- and tetracycline-based quadruple therapy for eradication of H.pylori in a group of Iranian patients with dyspepsia.
Patients and methods: Dyspeptic patients were randomly assigned in 2 groups and received omeprazole 20mg/twice a day, bismuth subcitrate 200mg/q6h, amoxicillin 1000mg/twice a day in association with furazolidone 100mg/ twice a day (OAB-F regimen) or tetracycline 500mg/ twice a day (OAB-T regimen). Stool antigen test was used to detect H. pylori eradication.
Results: Totally, 100 patients completed the desired regimen including 49 in OAB-F and 51 in OAB-T regimen. Following the first week, H. pylori was eradicated in 97.9% of OAB-F and 96% of OAB-T subjects, however, the difference did not reach a statistical significant level. These figures were 85.7% and 80.4% following the 4th week, respectively (NS).Conclusion: Both furazolidone-and tetracycline-based quadruple therapy were revealed to be effective for eradication of H.pylori, however, furazolidone is suggested for population resistant to metronidazole since it is cheaper and more available.